| As2O3联合格列卫对难治性慢性粒细胞白血病的靶向治疗 |
| |
| 引用本文： | 沈云峰,杨国华,朱华淳,蒋元强,周新,孙鸿丽,庄芸,孙超,毛玉文,张日.As2O3联合格列卫对难治性慢性粒细胞白血病的靶向治疗[J].江南大学学报(自然科学版),2005,4(6):649-652. |
| |
| 作者姓名： | 沈云峰 杨国华 朱华淳 蒋元强 周新 孙鸿丽 庄芸 孙超 毛玉文 张日 |
| |
| 作者单位： | 1. 南京医科大学,附属无锡第一医院血液科,江苏,无锡,214002
2. 苏州大学医学院,附属一院血液科,江苏,苏州,215006 |
| |
| 基金项目： | 江苏省卫生厅医学科技发展基金（H200206）资助课题. |
| |
| 摘 要： | 目的通过As2Ｏ3联合格列卫对Bac／Abl的作用靶点及二者药物作用无交叉耐药性的机制，达到使两种药发挥协同作用，更有效地治疗难治性慢性粒细胞白血病的目的．方法使用格列卫200～400mg／d，加As2Ｏ310mg／次，7～10 d／月作为一个周期，共用2～3个周期以评价疗效．结果9例均为单用榕列卫无效的患者，经联合使用后有3例达到血液学缓解，3例达到部分缓解，3例未缓解或恶化；9例均未达到细胞遗传学及分子生物学的缓解．结论对格列卫耐药的难治性慢性粒细胞白血病患者，继续联合应用As2O3，可以使部分患者达到缓解或部分缓解，二者无交叉耐药性并具有良好的协同作用．
|
| 关 键 词： | 慢性粒细胞性白血病 三氧化二砷 格列卫 靶向治疗 |
| 文章编号： | 1671-7147（2005）06-0649-04 |
| 收稿时间： | 2005-05-19 |
| 修稿时间： | 2005-05-192005-06-20 |
The Clinic Study of Targeted Therapy in the Refractory Chronic Myelocytic Leukemia by As2O3 Combined with Imatinib Mesylate |
| |
| SHEN Yun-feng,YANG Guo-hua,ZHU Hua-chun,JIANG Yun-qiang,ZHOU Xin,SUN Hong-li,ZHUAN Yun,SUN Chao,MAO Yu-wen,ZHANG Ri.The Clinic Study of Targeted Therapy in the Refractory Chronic Myelocytic Leukemia by As2O3 Combined with Imatinib Mesylate[J].Journal of Southern Yangtze University:Natural Science Edition,2005,4(6):649-652. |
| |
| Authors: | SHEN Yun-feng YANG Guo-hua ZHU Hua-chun JIANG Yun-qiang ZHOU Xin SUN Hong-li ZHUAN Yun SUN Chao MAO Yu-wen ZHANG Ri |
| |
| Institution: | 1. Department of Hematology, Wuxi First Hospital Affiliated to Nanjing Medical University, Wuxi 214002, China;2. Department of Hematology, the First Affiliated Hospital of Medical College of Suzhou University, Suzhou 215006, China |
| |
| Abstract: | OBJECTIVE To study the effectiveness of arsenic trioxide(As_2O_3) combined with Imatinib mesylate in refractory chronic myelocytic leukemia,because Imatinib and As_2O_3 have different effective target and have no across tolerance.METHOD Nine patients were treated with Imatinib 200~400 mg per day and As_2O_3 10 mg on day 1~10,one month as a cycle.We evaluated the effectiveness after 2~3 cycles.RESULT All patients who haven't effect with Imatinib mesylate alone were treated with above regimen,there were 3 complete remission(CR),3 partial remission(PR) and 3 non-responders(NR) or aggravation.But all nine patients had no respond in the aspect of cytogenetic and molecular biology.CONCLUSION Combined treatment of Imatinib mesylate with As_2O_3 may result in complete or partial remission in some patients who resistant to Imatinib alone.They have synergistic action but no across tolerance. |
| |
| Keywords: | chronic myelocytic leukemia As2O3 Imatinib mesylate targeted therapy |
| 本文献已被 CNKI 维普 万方数据 等数据库收录！ |
|
